This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Life Science Remove Medicine Remove Pharma R&D Related Topics
Bioinformatics Pharma Companies Clinical Research Protein Antibody Gene Development Regulation Drugs Research More Related Topics >
article thumbnail

EFPIA states AI rules must “enable not hinder” pharma R&D

Drug Discovery World

APRIL 24, 2024

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act.

Pharma R&D 52
Pharma R&D Medicine Development Regulation 52
article thumbnail

Rethinking the pharma R&D lifecycle with AI in mind

Drug Discovery World

AUGUST 7, 2024

Failing to reimagine R&D systems to handle the new speed and scale of AI-driven discovery risks over-promising and under-delivering to the people who need new medicines. The power of AI is being throttled by our R&D system There’s no question that new AI models for drug discovery deserve serious attention.

Pharma R&D 69
Pharma R&D Clinical Trials Clinical Trials Drugs 69
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024